MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas

S. Tura, F. Mandelli, P. Mazza, S. Pileri, F. Gherlinzoni, M. Bocchia, P. L. Zinzani, M. Fiacchini, M. Martelli, G. Papa, M. Antimi, M. F. Martelli, F. Grignani, B. Falini, F. Calabresi, E. M. Ruggeri, F. Dammacco, V. M. Lauta, G. Lucarelli, L. Moretti

Research output: Contribution to journalArticle

Abstract

From September 1988 two hundred -sixty - seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus F-MACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse- free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs, 42%). The degree Of hemathological and non-hematological toxicity was similar in both regimens. More reliable conclusions will be drawn after a longer follow-up.

Original languageEnglish
Pages (from-to)74-78
Number of pages5
JournalLeukemia
Volume5
Issue numberSUPPL. 1
Publication statusPublished - 1991

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Survival
Burkitt Lymphoma
Combination Drug Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Tura, S., Mandelli, F., Mazza, P., Pileri, S., Gherlinzoni, F., Bocchia, M., ... Moretti, L. (1991). MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas. Leukemia, 5(SUPPL. 1), 74-78.

MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas. / Tura, S.; Mandelli, F.; Mazza, P.; Pileri, S.; Gherlinzoni, F.; Bocchia, M.; Zinzani, P. L.; Fiacchini, M.; Martelli, M.; Papa, G.; Antimi, M.; Martelli, M. F.; Grignani, F.; Falini, B.; Calabresi, F.; Ruggeri, E. M.; Dammacco, F.; Lauta, V. M.; Lucarelli, G.; Moretti, L.

In: Leukemia, Vol. 5, No. SUPPL. 1, 1991, p. 74-78.

Research output: Contribution to journalArticle

Tura, S, Mandelli, F, Mazza, P, Pileri, S, Gherlinzoni, F, Bocchia, M, Zinzani, PL, Fiacchini, M, Martelli, M, Papa, G, Antimi, M, Martelli, MF, Grignani, F, Falini, B, Calabresi, F, Ruggeri, EM, Dammacco, F, Lauta, VM, Lucarelli, G & Moretti, L 1991, 'MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas', Leukemia, vol. 5, no. SUPPL. 1, pp. 74-78.
Tura S, Mandelli F, Mazza P, Pileri S, Gherlinzoni F, Bocchia M et al. MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas. Leukemia. 1991;5(SUPPL. 1):74-78.
Tura, S. ; Mandelli, F. ; Mazza, P. ; Pileri, S. ; Gherlinzoni, F. ; Bocchia, M. ; Zinzani, P. L. ; Fiacchini, M. ; Martelli, M. ; Papa, G. ; Antimi, M. ; Martelli, M. F. ; Grignani, F. ; Falini, B. ; Calabresi, F. ; Ruggeri, E. M. ; Dammacco, F. ; Lauta, V. M. ; Lucarelli, G. ; Moretti, L. / MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas. In: Leukemia. 1991 ; Vol. 5, No. SUPPL. 1. pp. 74-78.
@article{f7440a99693a4172b976fa98a08d18b3,
title = "MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas",
abstract = "From September 1988 two hundred -sixty - seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus F-MACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63{\%}) achieved a complete remission (CR), 17 complete responders have relapsed (29{\%}), and 21 have died (23{\%}), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76{\%}) achieved a CR, 9 complete responders have relapsed (14{\%}), and 11 pts have died (13{\%}), including 3 treatment related deaths. 30 months-projected survival is 64{\%} for MACOP-B treated pts compared to 84{\%} for F-MACHOP treated pts; 30 months-projected relapse- free survival is 80{\%} and 84{\%}, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82{\%} vs. 54{\%}) and in Burkitt-type lymphoblastic lymphoma (OS 100{\%} vs, 42{\%}). The degree Of hemathological and non-hematological toxicity was similar in both regimens. More reliable conclusions will be drawn after a longer follow-up.",
author = "S. Tura and F. Mandelli and P. Mazza and S. Pileri and F. Gherlinzoni and M. Bocchia and Zinzani, {P. L.} and M. Fiacchini and M. Martelli and G. Papa and M. Antimi and Martelli, {M. F.} and F. Grignani and B. Falini and F. Calabresi and Ruggeri, {E. M.} and F. Dammacco and Lauta, {V. M.} and G. Lucarelli and L. Moretti",
year = "1991",
language = "English",
volume = "5",
pages = "74--78",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas

AU - Tura, S.

AU - Mandelli, F.

AU - Mazza, P.

AU - Pileri, S.

AU - Gherlinzoni, F.

AU - Bocchia, M.

AU - Zinzani, P. L.

AU - Fiacchini, M.

AU - Martelli, M.

AU - Papa, G.

AU - Antimi, M.

AU - Martelli, M. F.

AU - Grignani, F.

AU - Falini, B.

AU - Calabresi, F.

AU - Ruggeri, E. M.

AU - Dammacco, F.

AU - Lauta, V. M.

AU - Lucarelli, G.

AU - Moretti, L.

PY - 1991

Y1 - 1991

N2 - From September 1988 two hundred -sixty - seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus F-MACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse- free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs, 42%). The degree Of hemathological and non-hematological toxicity was similar in both regimens. More reliable conclusions will be drawn after a longer follow-up.

AB - From September 1988 two hundred -sixty - seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus F-MACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse- free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs, 42%). The degree Of hemathological and non-hematological toxicity was similar in both regimens. More reliable conclusions will be drawn after a longer follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0025916634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025916634&partnerID=8YFLogxK

M3 - Article

C2 - 1716338

AN - SCOPUS:0025916634

VL - 5

SP - 74

EP - 78

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - SUPPL. 1

ER -